Cidara Therapeutics, Inc. (NASDAQ:CDTX – Get Free Report) shares gapped up prior to trading on Thursday after Needham & Company LLC raised their price target on the stock from $3.00 to $25.00. The stock had previously closed at $12.29, but opened at $14.50. Needham & Company LLC currently has a buy rating on the stock. Cidara Therapeutics shares last traded at $13.61, with a volume of 451,872 shares changing hands.
CDTX has been the subject of several other reports. HC Wainwright reaffirmed a “buy” rating and set a $120.00 target price on shares of Cidara Therapeutics in a report on Monday, April 8th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Cidara Therapeutics in a research report on Tuesday. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $71.25.
Read Our Latest Research Report on Cidara Therapeutics
Hedge Funds Weigh In On Cidara Therapeutics
Cidara Therapeutics Stock Performance
The firm has a market capitalization of $57.59 million, a P/E ratio of -2.63 and a beta of 0.98. The stock has a 50-day moving average of $15.35 and a 200 day moving average of $15.31.
Cidara Therapeutics Company Profile
Cidara Therapeutics, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.
See Also
- Five stocks we like better than Cidara Therapeutics
- How to Use High Beta Stocks to Maximize Your Investing Profits
- 3 Stocks Leading the U.S. Agriculture Comeback
- Using the MarketBeat Dividend Tax Calculator
- How to Use Put Debit Spreads to Profit From Falling Stocks
- Dividend Capture Strategy: What You Need to Know
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.